Impurity Profiling EXPLAINED
Developing robust analytical methods often hinges on the availability of highly characterized Reference Standards and Specific Impurities. Overlooking minor impurities during early synthesis stages can lead to catastrophic regulatory delays post-submission.
Mitigating Nitroso Risks
Recent regulatory focus on nitrosamine limits necessitates rigorous risk assessments. PEC Pharma synthesizes its own in-house reference impurities, enabling our labs to reliably quantify nitroso risk streams per ICH Q3/M7 compliance standards.
"You cannot control what you cannot accurately measure. Reliable reference standards are the anchors of our entire analytical ecosystem." - Chief Quality Officer
Interested in discussing this further?
Our team is available for technical discussions and CDMO partnership queries.
Contact Us Today

